Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China · Delayed Price · Currency is CNY 13.97
-0.04 (-0.29%)
Sep 15, 2026, 3:00 PM CST
SHA:600535 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,071 | 1,436 | 2,994 | 4,451 | 3,119 | 2,304 |
Short-Term Investments | 653.29 | 1,404 | - | - | - | - |
Trading Asset Securities | 2,292 | 1,394 | 524.72 | 300.71 | 1,125 | 1,487 |
Cash & Short-Term Investments | 4,016 | 4,234 | 3,518 | 4,751 | 4,244 | 3,791 |
Cash Growth | -5.00% | 20.34% | -25.95% | 11.95% | 11.95% | 78.94% |
Accounts Receivable | 2,472 | 2,418 | 1,966 | 2,131 | 3,348 | 3,796 |
Other Receivables | 41.21 | 39.96 | 23.06 | 11.49 | 8.98 | 9.47 |
Receivables | 2,513 | 2,458 | 1,989 | 2,142 | 3,357 | 3,805 |
Inventory | 1,458 | 1,427 | 1,712 | 1,748 | 1,532 | 1,548 |
Other Current Assets | 116.55 | 111.5 | 91.72 | 91.43 | 127.08 | 105 |
Total Current Assets | 8,104 | 8,230 | 7,311 | 8,733 | 9,260 | 9,249 |
Property, Plant & Equipment | 3,482 | 3,546 | 3,648 | 3,769 | 3,883 | 4,088 |
Long-Term Investments | 1,286 | 1,346 | 1,821 | 2,054 | 1,511 | 1,229 |
Goodwill | - | - | - | 15.88 | 15.88 | 167.08 |
Other Intangible Assets | 812.67 | 794.39 | 604.17 | 573.64 | 459.43 | 474.54 |
Long-Term Deferred Tax Assets | 88.45 | 67.05 | 53.17 | 50 | 88.29 | 60.79 |
Long-Term Deferred Charges | 1,307 | 1,333 | 1,466 | 1,476 | 1,157 | 1,193 |
Other Long-Term Assets | 221.56 | 22.66 | 72.54 | 43.14 | 102.08 | 79.68 |
Total Assets | 15,302 | 15,340 | 14,976 | 16,714 | 16,477 | 16,542 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 456.56 | 376.9 | 606.81 | 572.73 | 887.77 | 728.58 |
Accrued Expenses | 690.25 | 537.57 | 171.05 | 178.38 | 242.79 | 213.15 |
Short-Term Debt | 301.91 | 1,116 | 699.54 | 814.63 | 201.77 | 188.79 |
Current Portion of Long-Term Debt | 16.1 | 4.96 | 586.83 | 462.74 | 475.21 | 343.33 |
Current Portion of Leases | 42.08 | 49.7 | 47.84 | 58.54 | 53.98 | 55.67 |
Current Income Taxes Payable | 72.42 | 110.91 | 57.78 | 18.04 | 84.62 | 108.09 |
Current Unearned Revenue | 44.98 | 49.88 | 69.85 | 91.62 | 92.35 | 68.33 |
Other Current Liabilities | 45.51 | 62.39 | 109.98 | 172.88 | 108.72 | 149.12 |
Total Current Liabilities | 1,670 | 2,308 | 2,350 | 2,370 | 2,147 | 1,855 |
Long-Term Debt | 153.35 | 216.87 | 253.76 | 1,414 | 1,376 | 1,034 |
Long-Term Leases | 32.84 | 51.19 | 67.97 | 81.52 | 75.31 | 81.63 |
Long-Term Unearned Revenue | 207.71 | 189.95 | 193.29 | 159.02 | 177.79 | 214.57 |
Long-Term Deferred Tax Liabilities | 30.09 | 26.02 | 0.4 | 0.11 | 22.87 | 42.18 |
Total Liabilities | 2,094 | 2,792 | 2,865 | 4,024 | 3,799 | 3,228 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1,494 | 1,494 | 1,494 | 1,500 | 1,500 | 1,513 |
Additional Paid-In Capital | 482.35 | 482.39 | 458.96 | 958.08 | 1,457 | 1,530 |
Retained Earnings | 11,134 | 10,391 | 9,898 | 9,929 | 9,351 | 10,222 |
Treasury Stock | - | - | - | -105.98 | -105.98 | -251.29 |
Comprehensive Income & Other | -33.97 | 37.24 | 52.22 | 88 | 211.58 | -32.19 |
Total Common Equity | 13,076 | 12,404 | 11,903 | 12,368 | 12,412 | 12,981 |
Minority Interest | 131.7 | 143.49 | 207.86 | 321.59 | 265.12 | 332.56 |
Shareholders' Equity | 13,208 | 12,548 | 12,111 | 12,690 | 12,678 | 13,314 |
Total Liabilities & Equity | 15,302 | 15,340 | 14,976 | 16,714 | 16,477 | 16,542 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 546.28 | 1,438 | 1,656 | 2,831 | 2,182 | 1,704 |
Net Cash (Debt) | 3,469 | 2,795 | 1,862 | 1,920 | 2,062 | 2,088 |
Net Cash Growth | 36.96% | 50.10% | -2.99% | -6.89% | -1.23% | - |
Net Cash Per Share | 2.32 | 1.87 | 1.25 | 1.29 | 1.40 | 1.39 |
Filing Date Shares Outstanding | 1,494 | 1,494 | 1,494 | 1,494 | 1,494 | 1,499 |
Total Common Shares Outstanding | 1,494 | 1,494 | 1,494 | 1,494 | 1,494 | 1,499 |
Working Capital | 6,434 | 5,922 | 4,961 | 6,363 | 7,113 | 7,394 |
Book Value Per Share | 8.75 | 8.30 | 7.97 | 8.28 | 8.31 | 8.66 |
Tangible Book Value | 12,264 | 11,610 | 11,299 | 11,779 | 11,937 | 12,340 |
Tangible Book Value Per Share | 8.21 | 7.77 | 7.56 | 7.88 | 7.99 | 8.23 |
Buildings | 3,539 | 3,529 | 3,517 | 3,505 | 3,490 | 3,398 |
Machinery | 3,838 | 3,803 | 3,763 | 3,625 | 3,472 | 3,340 |
Construction In Progress | 395.07 | 322.42 | 221.76 | 153.87 | 102.96 | 167.85 |